The use of augmented or artificial intelligence (AI) in healthcare promises groundbreaking advancements, from increasing diagnostic accuracy and minimizing clinical errors to personalized treatment plans and automated clinical decision-making. Its use may allow us to transition from phenomenological categories of psychiatric illness to one driven by underlying etiology and realize the Research Domain Criteria (RDoC) model proposed by the (U.S.) National Institutes of Mental Health (NIMH), which today remains difficult to apply clinically and is accessible primarily to researchers. AI may facilitate the transition to a more syncretic framework of understanding psychiatric illness that accounts for disruptions, all the way from the cellular level to the level of social systems. Yet, despite immense possibilities, there are also associated risks. In this article, we explore the challenges and opportunities associated with the use of AI in psychiatry, focusing on the potential ethical and health equity considerations in vulnerable populations, especially in child and adolescent psychiatry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09540261.2024.2363374 | DOI Listing |
Int Dent J
March 2025
Department of Restorative Dentistry, College of Dentistry, Ajman University, Ajman, United Arab Emirates; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
Artificial intelligence (AI) holds immense promise in revolutionising dentistry, spanning, diagnostics, treatment planning and educational realms. This narrative review, in two parts, explores the fundamentals and the multifaceted potential of AI in dentistry. The current article explores the profound impact of AI in dentistry, encompassing diagnostic tools, treatment planning, and patient care.
View Article and Find Full Text PDFJ Clin Neurosci
March 2025
Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan; Department of Obstetrics and Gynecology, Koga Red Cross Hospital, 1150 Shimoyama, Koga, Ibaraki 306-0014, Japan; Medical Examination Center, Ibaraki Western Medical Center, 555 Otsuka, Chikusei, Ibaraki 308-0813, Japan. Electronic address:
J Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFAcute Crit Care
February 2025
Division of Pulmonary, and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!